Chronic heart failure patient and COVID-19: Focus on laboratory markers of myocardial damage

The aim of the study. To determine the severity of the current COVID-19 in patients with CHF. Materials and methods. The study included data from 98 patients diagnosed with COVID-19 in combination with CHF. The data on the duration of hospitalization, the severity of the lesion, the dynamics of the level of laboratory parameters are analyzed. Results. In 68 patients with CHF 2A, stage I of CHF in 27 patients and in 3 patients – stage 0. CHF of functional class I – 23 patients, FC II – 73 patients, FC III – 2 patients. The average duration of hospitalization was 15 days. Blood saturation (SpO2) in the range of 95–100 % was determined in 75 patients, 90–95 % – in 20 people, less than 90 % – in 3 patients. In 42.86 % of patients, an increase in the level of D-dimer was detected according to laboratory studies. Conclusions. Patients 60 years and older with CHF 2A and FC II with pronounced clinical symptoms are at risk of severe infection requiring hospitalization. Concomitant diseases of the cardiovascular system increase the duration of hospitalization.